Glaxosmithkline Pharmaceuticals Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 19, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2389 as of 18 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Sanjivani Paranteral Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,475 Cr while Market cap of Sanjivani Paranteral Ltd is 164 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd?

As of May 19, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2389.25. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹133.75.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.